Spyre Therapeutics, Inc.
DE ˙ DB ˙ US00773J2024
63,00 € ↑3,00 (5,00%)
2026-06-04
DEL PRIS
SecurityDE:3920 / Spyre Therapeutics, Inc.
InstitutionNorthern Trust Corp
Latest Disclosed Ownership578,907 shares
Latest Disclosed Value $ 29,200,068
Northern Trust Corp reports 3.19% increase in ownership of 3920 / Spyre Therapeutics, Inc.

On May 14, 2026 - Northern Trust Corp filed a 13F-HR form disclosing ownership of 578,907 shares of Spyre Therapeutics, Inc. (DE:3920) valued at $22,924,717 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 561,023 shares of Spyre Therapeutics, Inc.. This represents a change in shares of 3.19% during the quarter. The current value of the position is $36,471,141 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F SPYRE THERAPEUTICS COM NEW 00773J202 578,907 17,884 3.19 29,200 58.88 0.0008
2026-02-17 2025-12-31 13F SPYRE THERAPEUTICS COM NEW 00773J202 561,023 118,987 26.92 18,379 148.10 0.0005
2025-11-14 2025-09-30 13F SPYRE THERAPEUTICS COM NEW 00773J202 442,036 5,089 1.16 7,409 13.25 0.0009
2025-08-13 2025-06-30 13F SPYRE THERAPEUTICS COM NEW 00773J202 436,947 57,072 15.02 6,541 6.72 0.0009
2025-05-13 2025-03-31 13F SPYRE THERAPEUTICS COM NEW 00773J202 379,875 30,892 8.85 6,129 -24.56 0.0009
2025-02-14 2024-12-31 13F SPYRE THERAPEUTICS COM NEW 00773J202 348,983 34,693 11.04 8,124 -12.11 0.0012
2024-11-13 2024-09-30 13F SPYRE THERAPEUTICS COM 00773J202 314,290 228,702 267.21 9,243 359.39 0.0015
2024-08-14 2024-06-30 13F SPYRE THERAPEUTICS COM 00773J202 85,588 19,248 29.01 2,012 -20.03 0.0003
2024-05-14 2024-03-31 13F SPYRE THERAPEUTICS COM 00773J202 66,340 66,340 2,516 0.0004
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.